Edition:
United States

BioXcel Therapeutics Announces FDA Acceptance Of IND For Lead Cancer Drug


Monday, 5 Nov 2018 04:00am EST 

Nov 5 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND FOR LEAD IMMUNO-ONCOLOGY CANDIDATE, BXCL701, IN TREATMENT EMERGENT NEUROENDOCRINE PROSTATE CANCER.BIOXCEL THERAPEUTICS INC - FIRST-IN-HUMAN PHASE 1B / 2 COMBINATION TRIAL OF BXCL701 AND PEMBROLIZUMAB (KEYTRUDA®) EXPECTED TO INITIATE IN 4Q 2018.BIOXCEL THERAPEUTICS INC - EFFICACY STUDY WITH OBJECTIVE RESPONSE RATE ENDPOINT TO ENROLL UP TO 40 PATIENTS AT MULTIPLE CLINICAL SITES.